Project Grant R01AI195676
Award Date 8/19/26
Completion Date 7/31/31
Dollars Obligated $803K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (doing business as Cleveland Clinic Lou Ruvo Center) $608,840 on July 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the metabolic drivers of donor-specific antibody generation in solid organ transplant recipients. The project...
- The National Institute of Allergy and Infectious Diseases awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $690,359 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulation of donor-specific antibody production in kidney transplantation. The research addresses antibody-mediated rejection (ABMR), a leading cause of renal transplant loss, by examining the role of lymphocyte activation gene 3...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $444,125 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to accelerate T cell immune reconstitution following cultured thymus tissue implantation (CTTI). The research addresses the urgent clinical need to speed immune recovery after thymus transplantation, which currently risks early post-transplant deaths from infection before immune reconstitution occurs. Duke's prior...
- The National Institute of Allergy and Infectious Diseases awarded Beckman Research Institute of the City of Hope $888,941 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct preclinical research on regulatory T cell-mediated thymic regeneration after hematopoietic cell transplantation. The research addresses thymic injury caused by allogeneic hematopoietic cell transplantation preconditioning, which increases risk of malignancies,...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $847,299 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate immunomodulatory mechanisms in allograft rejection. The project, titled "Regulation of Alloimmunity by Intragraft Endothelial Cells," examines how graft microvascular endothelial cells suppress alloimmune responses during transplant rejection. The research will characterize...
- The National Institute of Allergy and Infectious Diseases awarded Case Western Reserve University $110,228 on November 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize selective inhibitors of transcriptional activation (SITAs) as therapeutics for pathological T cell activation. The research investigates the mechanism by which SITAs—novel molecules that covalently bind to exportin-1 (XPO1) at the C528 position—inhibit T cell activation despite...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $822,280 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on intragraft alloreactive T cells in human solid organ transplantation, with the goal of controlling rejection after transplantation. The research dissects intragraft T cell alloimmunity using longitudinal surveillance biopsies from intestinal...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $1,177,657 on July 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the biophysical and structural basis of T cell selection at the intersection of conventional and regulatory T cell repertoires. The research addresses autoimmune disease pathogenesis by examining how CD4+ T cells recognize peptide antigens complexed with MHC class II molecules through the T...
- The National Institute of Allergy and Infectious Diseases awarded ST Jude Children's Research Hospital Inc. $277,500 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer a synthetic IL-33 receptor that enhances T-cell function for treating autoimmune disorders and cancer. The research systematically examines regulatory nodes governing T-cell differentiation and function, including environmental cues, signaling pathways, metabolism,...
- The National Institute of Allergy and Infectious Diseases awarded Cincinnati Children's Hospital Medical Center $243,000 on May 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to model fibroblast-cholangiocyte interactions in chronic ductopenic rejection using primary human cholangiocyte organoids. Chronic ductopenic rejection is the most common immunologic cause of liver allograft loss in children. The research uses human liver tissue samples and...